Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114028 | 0.69 | HIPK2 (0.41) | HIPK2ALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL9515906 | 0.68 | — | — | |
| SCHEMBL2068718 | 0.64 | HIPK2 (0.35) | HIPK2ALDH1A1SMN1; SMN2ALOX15 | |
| SCHEMBL7015002 | 0.64 | — | — | |
| SCHEMBL333104 | 0.62 | CYP3A4 (0.41) | HIPK2ALOX15 | |
| SCHEMBL308284 | 0.62 | F2RL1 (0.41) | HIPK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4456263 | 0.61 | KDM4E (0.47) | ALDH1A1 | |
| SCHEMBL3582119 | 0.61 | HIPK2 (0.36) | HIPK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL753318 | 0.61 | HIPK2 (0.36) | HIPK2ALDH1A1SMN1; SMN2 | |
| SCHEMBL8648296 | 0.61 | HIPK2 (0.36) | HIPK2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015173321-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING A PARTICULAR IMIDAZOLE COUPLER AND AN OXIDATION BASE | L'OREAL (FR) | 2015-11-19 | — | — | WO | claimed |
| US-8071616-B2 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2011-12-06 | — | — | US | claimed |
| US-20100152251-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | DUMAS JACQUES | 2010-06-17 | — | — | US | claimed |
| US-7678811-B2 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | claimed |
| US-20070265315-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC | 2007-11-15 | — | — | US | claimed |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | BAYER CORPORATION | 2003-11-20 | — | — | US | claimed |
| WO-2003068229-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2015173321-A1 | COMPOSITION FOR DYEING KERATIN FIBRES, COMPRISING A PARTICULAR IMIDAZOLE COUPLER AND AN OXIDATION BASE | L'OREAL (FR) | 2015-11-19 | — | — | WO | disclosed |
| EP-1972623-A1 | Arylpyridazines as fungicides | Bayer CropScience AG (DE) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265315-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | MAP2K2, MAP3K7, MAP4K2 | HIPK2 270/4885ALDH1A1 1985/4885SMN1; SMN2 4261/4885 |
| US-20030216396-A1 | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors | MAP2K2, MAP2K7, MAPK1 | HIPK2 273/4885ALDH1A1 2400/4885SMN1; SMN2 4282/4885 |
| US-20100152251-A1 | PYRIDINE, QUINOLINE, AND ISOQUINOLINE N-OXIDES AS KINASE INHIBITORS | MAP2K2, MAP2K7, MAPK1 | HIPK2 273/4885ALDH1A1 2400/4885SMN1; SMN2 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.